TL;DR
The FDA is removing 12 peptides, including BPC-157 and GHK-Cu, from its Category 2 list of bulk drug substances. This move, announced by Secretary Kennedy, aims to restore regulated access through compounding pharmacies and curb the dangerous black market. These peptides will now undergo rigorous scientific evaluation by
